At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…
Read More
With nutriceuticals regularly making headlines for their alleged benefits in the treatment or prevention of cancer, some clinicians are endeavouring to scientifically investigate claims and dispel fake news that can give false hope to patients….
Read More
A combination of chemotherapy and endocrine therapy offers the promise of long-term recurrence-free survival for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer, despite having a biologically high risk of disease recurrence. Yesterday’s Late-Breaking…
Read More
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer. Result from the BEACON study have shown for the first time that a combination of three…
Read More
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge. Advances in cancer research and the regulatory approval of new agents do not usually…
Read More
Rechallenge with PD-1/PD-L1 inhibitors after a (un)planned interruption may offer a potential safety net for patients with disease progression. At ESMO Congress 2019, results from a study systematically investigating this approach for the first time…
Read More
The phase III trial confirms that targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy, but debate is open on whether results are clinically meaningful. In view of encouraging results in the treatment…
Read More